secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001193125-23-001510
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks updates cash guidance to ~$490M; CMO Josephson removed; new early-stage development head appointed
--------------------------------------------------------------------------------

- Preliminary unaudited cash (cash, equivalents, marketable debt) ~$490M as of Dec 31, 2022, plus ~$30M expected Q4 zanidatamab reimbursement from Jazz.
- Cash runway extended to at least end of 2026; net operating cash burn guided at $90-120M for 2023 including ~$15M capex.
- Dr. Neil Josephson removed as Chief Medical Officer effective Jan 3, 2023; Dr. Jeffrey Smith appointed SVP Early-Stage Development.
- Zanidatamab full HERIZON-BTC-01 data expected H1 2023; zanidatamab zovodotin RP2D set at 2.5 mg/kg Q3W with expansion into breast cancer cohorts.
- Promotions: Mark Hollywood to EVP Technical & Manufacturing; Daniel Dex to General Counsel & Corporate Secretary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523001510/0001193125-23-001510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523001510/d389002d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-001510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer